Coronary Artery Disease Clinical Trials Analysis 2025: Novel Antithrombotics, Regenerative Therapies, and Precision Approaches Drive Innovation | DelveInsight

DelveInsight's "Coronary Artery Disease (CAD) - Clinical Trials Analysis, 2025" explores a diverse pipeline targeting the world's leading cause of morbidity and mortality. Despite the availability of statins, antiplatelets, and interventional procedures, residual risk and recurrent cardiovascular events remain major challenges.

Ongoing clinical trials are advancing novel antithrombotic agents with improved safety, regenerative therapies such as stem cell-derived approaches for myocardial repair, and gene-based strategies aimed at lipid and vascular modulation. Precision medicine trials using AI-driven risk stratification and biomarker-guided therapies are also gaining momentum, aiming to personalize treatment and improve outcomes.

With multiple late-stage studies set to report in the coming years, the CAD pipeline is positioned to transform care by addressing unmet needs, reducing long-term complications, and advancing beyond conventional lipid-lowering and revascularization strategies.

Explore the full pipeline analysis for coronary artery disease and uncover key opportunities @ https://www.delveinsight.com/report-store/coronary-artery-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Coronary Artery Disease Pipeline Report
• DelveInsight's Coronary Artery Disease Pipeline analysis depicts a robust space with 30+ active players working to develop 25+ pipeline drugs for Coronary Artery Disease treatment.
• The leading Coronary Artery Disease companies include Idorsia Pharmaceuticals, AstraZeneca, Sinotau Pharmaceuticals, XyloCor Therapeutics, AdvanceCor, Sinotau Pharmaceuticals, GE Healthcare, Honya Medical Inc, AstraZeneca, Helixmith, Amgen, Angionetics, Xylocor Therapeutics, Regio Biosciences, and others are evaluating their lead assets to improve the Coronary Artery Disease treatment landscape.
• Key Coronary Artery Disease pipeline therapies in various stages of development include Selatogrel, XTR 003, AdVEGFXC1, Revacept, XTR004, MCRcI stem cells, PET MPI, Inclisiran, AZD-5718, VM202, Evolocumab, Ad5-FGF4, REG-101, and others.
• In June 2025, Artrya Limited (ASX: AYA) announced it filed a 510(k) pre-market submission with the U.S. FDA for its Salix® Coronary Plaque module, part of its AI-powered Salix® platform for near real-time coronary artery disease assessment and management.
• In March 2025, Caristo Diagnostics announced it received FDA 510(k) clearance for its CaRi-PlaqueTM technology, an AI-assisted image analysis application designed to aid in the diagnosis of coronary artery disease (CAD).
• In March 2025, the FDA approved the first generics of Xarelto (rivaroxaban) 2.5 mg tablets, an anticoagulant to prevent deep vein thrombosis in adults with peripheral artery disease and to reduce the risk of major cardiovascular events in adults with coronary artery disease.
• In November 2024, HeartLung Technologies, a Houston-based AI company, announced that it has received 510(k) clearance from the U.S. FDA for its new software, AutoChamber. This software assesses chest CT scans for indicators of coronary artery disease (CAD) and other serious heart conditions, focusing on opportunistic heart evaluations.
• In September 2024, SpectraWAVE, Inc., a medical imaging company dedicated to enhancing treatment and outcomes for patients with coronary artery disease (CAD), announced that it raised $50 million in a Series B funding round.
• In September 2024, GE HealthCare (Nasdaq: GEHC) announced FDA approval of FlyrcadoTM (flurpiridaz F 18), the first positron emission tomography myocardial perfusion imaging (PET MPI) agent for detecting coronary artery disease (CAD)

Request a sample and discover the recent breakthroughs happening in the Coronary Artery Disease pipeline landscape @ https://www.delveinsight.com/report-store/coronary-artery-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Coronary Artery Disease Overview
Coronary artery disease (CAD), or coronary heart disease, is a condition where the coronary arteries become narrowed or blocked, reducing blood flow to the heart muscle. This is often caused by cholesterol buildup (plaques) and inflammation. When the heart doesn't receive enough oxygen-rich blood, symptoms like chest pain (angina) and shortness of breath can occur. A complete blockage may lead to a heart attack. CAD usually develops slowly over decades, with symptoms often remaining unnoticed until significant blockage or a heart attack happens.

Find out more about Coronary Artery Disease medication @ https://www.delveinsight.com/report-store/coronary-artery-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr.

Coronary Artery Disease Treatment Analysis: Drug Profile
Flurpiridaz F-18: GE Healthcare
Flurpiridaz F-18 is a fluorine-18-labeled imaging agent developed by Lantheus Medical Imaging for the diagnosis of coronary artery disease (CAD), the leading cause of heart disease. This investigational positron emission tomography (PET) myocardial perfusion imaging (MPI) agent is being evaluated in clinical trials. GE Healthcare has initiated a second Phase III clinical trial to assess the use of Flurpiridaz F-18 Injection in PET MPI for detecting CAD. The agent is currently in Phase III clinical trials for the treatment of coronary artery disease.

Evolocumab: Amgen
Evolocumab injection is used to reduce the risk of stroke, heart attack, or the need for coronary artery bypass graft (CABG) surgery in individuals with cardiovascular disease. It is also used, either alone or in combination with other cholesterol-lowering treatments such as statins or ezetimibe (Zetia), to lower low-density lipoprotein (LDL) cholesterol levels, also known as "bad cholesterol." In patients with familial heterozygous hypercholesterolemia or homozygous familial hypercholesterolemia, Evolocumab helps reduce LDL cholesterol through its action as a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor monoclonal antibody. By blocking the production of LDL cholesterol, it helps prevent cholesterol buildup in the arteries, improving blood flow to vital organs like the heart and brain. Evolocumab is currently in Phase III clinical trials for the treatment of coronary artery disease.

Learn more about the novel and emerging Coronary Artery Disease pipeline therapies @ https://www.delveinsight.com/report-store/coronary-artery-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Coronary Artery Disease Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Coronary Artery Disease Pipeline Report
• Coverage: Global
• Key Coronary Artery Disease Companies: Idorsia Pharmaceuticals, AstraZeneca, Sinotau Pharmaceuticals, XyloCor Therapeutics, AdvanceCor, Sinotau Pharmaceuticals, GE Healthcare, Honya Medical Inc, AstraZeneca, Helixmith, Amgen, Angionetics, Xylocor Therapeutics, Regio Biosciences, and others.
• Key Coronary Artery Disease Pipeline Therapies: Selatogrel, XTR 003, AdVEGFXC1, Revacept, XTR004, MCRcI stem cells, PET MPI, Inclisiran, AZD-5718, VM202, Evolocumab, Ad5-FGF4, REG-101, and others.

Dive deep into rich insights for drugs used for Coronary Artery Disease treatment; visit @ https://www.delveinsight.com/report-store/coronary-artery-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Coronary Artery Disease Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Coronary Artery Disease Pipeline Therapeutics
6. Coronary Artery Disease Pipeline: Late-Stage Products (Phase III)
7. Coronary Artery Disease Pipeline: Late-Stage Products (Phase III)
8. Coronary Artery Disease Pipeline: Mid-Stage Products (Phase II)
9. Coronary Artery Disease Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.